Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Transgene    TNG   FR0005175080

TRANSGENE

(TNG)
  Report
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Paris
07/07/2020 07/08/2020 07/09/2020 07/10/2020 07/13/2020 Date
1.49(c) 1.474(c) 1.486(c) 1.44(c) 1.456 Last
49 950 29 125 216 207 51 783 21 881 Volume
+3.47% -1.07% +0.81% -3.10% +1.11% Change
More quotes
Financials
Sales 2020 87,0 M 98,5 M 98,5 M
Net income 2020 28,2 M 31,9 M 31,9 M
Net cash position 2020 52,6 M 59,6 M 59,6 M
P/E ratio 2020 4,24x
Yield 2020 -
Sales 2021 12,1 M 13,7 M 13,7 M
Net income 2021 -38,9 M -44,1 M -44,1 M
Net cash position 2021 13,1 M 14,8 M 14,8 M
P/E ratio 2021 -3,06x
Yield 2021 -
Capitalization 120 M 136 M 136 M
EV / Sales 2020 0,78x
EV / Sales 2021 8,88x
Nbr of Employees 136
Free-Float 35,1%
More Financials
Company
Transgene, part of Institut Mérieux, is a publicly traded French biopharmaceutical company focused on discovering and developing targeted immunotherapies for the treatment of cancer and infectious diseases. Transgene's programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells. The company's four lead clinical-stage programs are: TG4001 for HPV positive... 
More about the company
Latest news on TRANSGENE
07/09TRANSGENE : July 9, 2020 - Transgene and Hypertrust Patient Data Care announce s..
PU
07/09TRANSGENE : 9 juillet 2020 - Transgene et Hypertrust Patient Data Care déploient..
PU
07/09TRANSGENE : and Hypertrust Patient Data Care Announce Successful Go-Live of the ..
BU
07/06TRANSGENE : Half-Year Report on the Transgene Liquidity Contract with Natixis Od..
BU
06/22TRANSGENE : Presents Promising New Data from its Next-Generation Immunotherapy P..
BU
06/22TRANSGENE : 's and BioInvent's BT-001 Achieves Outstanding Tumor Cure Rates in P..
BU
05/27TRANSGENE : May 27, 2020 - Combined General Meeting of May 27, 2020
PU
05/27TRANSGENE : Combined General Meeting of May 27, 2020
BU
05/15TRANSGENE : May 15, 2020 - Transgene and BioInvent present preclinical data demo..
PU
05/15TRANSGENE : and BioInvent Present Preclinical Data Demonstrating BT-001's Powerf..
BU
05/15TRANSGENE : May 15, 2020 - Transgene and NEC demonstrate high accuracy of AI-bas..
PU
05/15TRANSGENE : and NEC Demonstrate High Accuracy of AI-Based Neoantigen Prediction ..
BU
05/06TRANSGENE : May 6, 2020 - Transgene reports Q1 2020 financial position and busin..
PU
05/06TRANSGENE : Reports Q1 2020 Financial Position and Business Update
BU
05/06TRANSGENE : 1st quarter earnings
CO
More news
News in other languages on TRANSGENE
07/09TRANSGENE : plus forte hausse du SRD à la mi-séance du jeudi 9 juillet 2020
07/09Les valeurs à suivre aujourd'hui à Paris Jeudi 9 juillet 2020
07/09TRANSGENE : et Hypertrust Patient Data Care déploient une solution de blockchain..
07/09TRANSGENE : July 9, 2020 - Transgene and Hypertrust Patient Data Care announce s..
07/09TRANSGENE : 9 juillet 2020 - Transgene et Hypertrust Patient Data Care déploient..
More news
Chart TRANSGENE
Duration : Period :
Transgene Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TRANSGENE
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 2
Average target price 2,50 €
Last Close Price 1,44 €
Spread / Highest target 122%
Spread / Average Target 73,6%
Spread / Lowest Target 25,0%
EPS Revisions
Managers
NameTitle
Philippe Archinard Chairman & Chief Executive Officer
Jean-Philippe Del Vice President-Finance
Eric Quéméneur Deputy CEO, Director-Research & Development
Hemanshu Shah VP-Medical Affairs & International Development
Maud Brandely VP-Clinical Operations & Regulatory Affairs
Sector and Competitors
1st jan.Capitalization (M$)
TRANSGENE-7.10%136
GILEAD SCIENCES, INC.17.45%95 734
VERTEX PHARMACEUTICALS34.48%76 344
REGENERON PHARMACEUTICALS65.35%63 051
WUXI APPTEC CO., LTD.53.97%33 311
GENMAB A/S56.13%22 955